We visited five of First REIT’s assets in Jakarta – four hospitals and a hotel & country club – over 21-22nd March 2023. All four of the hospitals we visited, Siloam Hospitals Lippo Village (SHLV), Siloam Hospitals Kebon Jeruk (SHKJ), Siloam Hospitals TB Simatupang, and Mochtar Riady Comprehensive Cancer Centre (MRCCC), were part of the 13 hospitals that had leases restructured effective Jan 2021 for a lease term of 15 years. The other asset visited was Imperial Aryaduta Hotel & Country Club (IAHCC), which is a non-core asset and is being marketed for sale. It has its lease expiring in Dec 2023.
Company Background
First REIT (FIRT) is Singapore’s first healthcare REIT that focuses on investing in income-producing real estate assets that are primarily used for healthcare-related purposes. Its S$1,145.3mn portfolio consists of 32 properties comprising 15 in Indonesia (72.1% of AUM), 14 in Japan (25.1%), and 3 in Singapore (2.8%). FIRT’s sponsors are OUE Limited and OUE Lippo Healthcare Limited (OUELH). FIRT has the right-of-first-refusal (ROFR) from OUELH, and a ROFR to a pipeline of hospitals from Lippo Karawachi (LPKR), a majority shareholder of Siloam.
The Lease Structure
The restructured Master Lease Agreement (MLA) that took effect in Jan 2021 for its Indonesia hospitals (excluding Lippo Cikarang whose lease expires Dec 2025) is the higher of an annual fixed base rent escalation of 4.5% or 8% of the hospital’s Gross Operating Revenue (GOR) in the preceding financial year and is denominated in IDR.
Based on the terms of the restructured MLA, Siloam and LPKR will pay 6.5% and 1.5% of the preceding year’s GOR respectively after FY26 assuming performance-based rent is achieved. As a result, Siloam’s direct rental contribution is projected to rise from c.50% in FY22 to c.80% in the long term. This brings more assurance of future rental collections, as before the restructuring LPKR contributed most of the rent. Siloam continues to see strong operating cash flow since FY20 due to steady growth in non-COVID patient volumes, while LPKR has been in the red since FY19.
Singapore properties have a fixed base rental and a fixed annual increment of 2%. For most of the Japan properties, rental may be revised upwards every 2 to 3 years upon negotiation based on the increase in Japan’s CPI or interest rates. Most of FIRT’s properties are on triple net lease terms.
Site Visit Highlights
Tertiary care hospitals provide highly specialised consultative care and handle more complex cases. They have higher revenue intensity per patient and margins compared to primary and secondary care hospitals. Each of FIRT’s hospital has its own “Centre of Excellence”, which focuses on selective branches of medicine such as Neuroscience, Cardiology and Oncology. The resident and practising doctors are some of the nation’s best in their respective fields, drawing patients from all the country.
The hospitals we visited had undergone or are undergoing Asset Enhancement Initiatives (AEI) to improve customer experience and facilities, at the expense of the operators themselves.
Investment Actions
No stock rating or price target provided, as we do not have coverage on FIRT.
Descriptions of the visited assets
Siloam Hospitals Lippo Village (SHLV)
This JCI-accredited 28-year-old hospital specialises in cardiology, neuroscience and orthopaedics and has a capacity of 308 beds. It is also the only private hospital in Jakarta that can do gamma knife surgery – the other being a government-owned one. It has a newly renovated reception and pharmacy area to enhance customer experience.
Siloam Hospitals Kebon Jeruk (SHKJ)
SHKJ is a 32-year-old, 250-bed facility which specialises in Cardiology, Orthopaedics and Urology. It is also JCI-accredited and is one of the hospitals in FIRT’s portfolio that is contributing performance-based rent. There are plans for renovations as the building is old.
Mochtar Riady Comprehensive Cancer Centre (MRCCC)
MRCCC is a 29-storey 13-year-old asset specialising in Emergency & Trauma, Gastroenterology and Oncology. This 334-bed hospital is equipped with state-of-the-art facilities and technologies to offer the most comprehensive cancer treatments and is strategically located in prime district in Central Jakarta.
Siloam Hospitals TB Simatupang (SHTBS)
A 10-year-old 16-storey hospital with the capacity of 269 beds. It is famous for its wellness centre and specialises in Cardiology, Neuroscience and Oncology.
Imperial Aryaduta Hotel & Country Club (IAHCC)
IAHCC comprises a 7-storey hotel building and 6 blocks of cabana houses with a 2-story country club. It is a 4-star hotel and has 191 hotel guest rooms. IAHCC enjoys an average occupancy of 80% with room rates back to pre-Covid levels. As IAHCC is a non-core asset, it is being marketed for sale.
Comments
The biggest concern for FIRT is whether LPKR can continue to pay the rental but with its percentage of rental contribution going down from c.88% before the restructuring of the master leases to c.50% in FY22, to less than 20% in the long run due to the new MLA, FIRT’s risk profile has improved.
First REIT’s 2.0 growth strategy to increase its portfolio in developed markets to >50% AUM by 2027 is in motion, as seen from its 14 nursing homes acquisition in Japan in FY22, bringing its current weightage to more than a quarter. We are optimistic for more acquisitions in Japan, where capitalization rates remain stable and interest rates are low.
First REIT has also been benefitting from the strong Singapore Dollar as some Indonesian patients at its hospitals, who used to travel to Singapore for medical tourism, decided to seek treatment locally as it becomes more costly in Singapore. Other potential customers could be from the South East Asia region, where they look to other alternatives instead of Singapore to seek treatment due to affordability reasons.
As most rental revenue from Indonesia is collected in IDR after the restructured MLA, First REIT is more susceptible to currency risk. However, the 4.5% annual rental escalation for its Indonesia hospitals helps to mitigate this risk.
First REIT is currently trading at 0.85x P/NAV with a dividend yield of 10.1%.
Important Information
This report is prepared and/or distributed by Phillip Securities Research Pte Ltd ("Phillip Securities Research"), which is a holder of a financial adviser’s licence under the Financial Advisers Act, Chapter 110 in Singapore.
By receiving or reading this report, you agree to be bound by the terms and limitations set out below. Any failure to comply with these terms and limitations may constitute a violation of law. This report has been provided to you for personal use only and shall not be reproduced, distributed or published by you in whole or in part, for any purpose. If you have received this report by mistake, please delete or destroy it, and notify the sender immediately.
The information and any analysis, forecasts, projections, expectations and opinions (collectively, the “Research”) contained in this report has been obtained from public sources which Phillip Securities Research believes to be reliable. However, Phillip Securities Research does not make any representation or warranty, express or implied that such information or Research is accurate, complete or appropriate or should be relied upon as such. Any such information or Research contained in this report is subject to change, and Phillip Securities Research shall not have any responsibility to maintain or update the information or Research made available or to supply any corrections, updates or releases in connection therewith.
Any opinions, forecasts, assumptions, estimates, valuations and prices contained in this report are as of the date indicated and are subject to change at any time without prior notice. Past performance of any product referred to in this report is not indicative of future results.
This report does not constitute, and should not be used as a substitute for, tax, legal or investment advice. This report should not be relied upon exclusively or as authoritative, without further being subject to the recipient’s own independent verification and exercise of judgment. The fact that this report has been made available constitutes neither a recommendation to enter into a particular transaction, nor a representation that any product described in this report is suitable or appropriate for the recipient. Recipients should be aware that many of the products, which may be described in this report involve significant risks and may not be suitable for all investors, and that any decision to enter into transactions involving such products should not be made, unless all such risks are understood and an independent determination has been made that such transactions would be appropriate. Any discussion of the risks contained herein with respect to any product should not be considered to be a disclosure of all risks or a complete discussion of such risks.
Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of any product. Any decision to purchase any product mentioned in this report should take into account existing public information, including any registered prospectus in respect of such product.
Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may provide an array of financial services to a large number of corporations in Singapore and worldwide, including but not limited to commercial / investment banking activities (including sponsorship, financial advisory or underwriting activities), brokerage or securities trading activities. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have participated in or invested in transactions with the issuer(s) of the securities mentioned in this report, and may have performed services for or solicited business from such issuers. Additionally, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have provided advice or investment services to such companies and investments or related investments, as may be mentioned in this report.
Phillip Securities Research or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report may, from time to time maintain a long or short position in securities referred to herein, or in related futures or options, purchase or sell, make a market in, or engage in any other transaction involving such securities, and earn brokerage or other compensation in respect of the foregoing. Investments will be denominated in various currencies including US dollars and Euro and thus will be subject to any fluctuation in exchange rates between US dollars and Euro or foreign currencies and the currency of your own jurisdiction. Such fluctuations may have an adverse effect on the value, price or income return of the investment.
To the extent permitted by law, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may at any time engage in any of the above activities as set out above or otherwise hold an interest, whether material or not, in respect of companies and investments or related investments, which may be mentioned in this report. Accordingly, information may be available to Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, which is not reflected in this report, and Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may, to the extent permitted by law, have acted upon or used the information prior to or immediately following its publication. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited its officers, directors, employees or persons involved in the issuance of this report, may have issued other material that is inconsistent with, or reach different conclusions from, the contents of this report.
The information, tools and material presented herein are not directed, intended for distribution to or use by, any person or entity in any jurisdiction or country where such distribution, publication, availability or use would be contrary to the applicable law or regulation or which would subject Phillip Securities Research to any registration or licensing or other requirement, or penalty for contravention of such requirements within such jurisdiction.
This report is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. The products mentioned in this report may not be suitable for all investors and a person receiving or reading this report should seek advice from a professional and financial adviser regarding the legal, business, financial, tax and other aspects including the suitability of such products, taking into account the specific investment objectives, financial situation or particular needs of that person, before making a commitment to invest in any of such products.
This report is not intended for distribution, publication to or use by any person in any jurisdiction outside of Singapore or any other jurisdiction as Phillip Securities Research may determine in its absolute discretion.
IMPORTANT DISCLOSURES FOR INCLUDED RESEARCH ANALYSES OR REPORTS OF FOREIGN RESEARCH HOUSE
Where the report contains research analyses or reports from a foreign research house, please note:
Darren has over three years of experience on the buy-side as a fund manager. During his time as fund manager, he has managed multiple funds and mandates including dividend income, growth, customised, Singapore focused and regionally focused funds. He graduated from the University of London with a First-Class Honours degree in Banking and Finance.
